Evidence map›Paper›PMID 33676851›Full record

ArticleUrologic oncology2021

Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus.

Wei Phin Tan, Ardeshir R Rastinehad, Laurence Klotz, Peter R Carroll, Mark Emberton, John F Feller, Arvin K George, Inderbir S Gill, Rajan T Gupta, Aaron E Katz and 11 more

Open access · greenAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 16 institutions in 5 countries.

Wei Phin TanDivision of Urology, Duke University Medical Center, Durham, NC.
Ardeshir R RastinehadDepartment of Urology, Northwell Health, New York City, NY.
Laurence KlotzDepartment of Urology, University of Toronto, Toronto, Ontario.
Peter R CarrollDepartment of Urology, University of California San Francisco, San Francisco, CA.
Mark EmbertonDivision of Surgery and Interventional Science, University College London, London, United Kingdom.
John F FellerHALO Diagnostics, Indian Wells, CA.
Arvin K GeorgeDepartment of Urology, University of Michigan, Ann Arbor, MI.
Inderbir S GillDepartment of Urology, University of Southern California, Los Angeles, CA.
Rajan T GuptaDepartment of Radiology, Duke University Medical Center, Durham, NC.
Aaron E KatzDepartment of Urology, New York University, New York City, NY.
Amir H LebastchiDepartment of Urology, University of Southern California, Los Angeles, CA.
Leonard S MarksDepartment of Urology, University of California Los Angeles, Los Angeles, CA.
Giancarlo MarraL'Institut Mutualiste Montsouris, Paris, France.
Peter A PintoUrologic Oncology Branch of the National Cancer Institute, Bethesda, MD.
Daniel Y SongDepartment of Radiation Oncology, Johns Hopkins University, Baltimore, MD.
Abhinav SidanaDepartment of Urology, University of Cincinnati, Cincinnati, OH.
John F WardDepartment of Urology, MD Anderson Cancer Center, Houston, TX.
Rafael Sanchez-SalasL'Institut Mutualiste Montsouris, Paris, France.
Jean de la RosetteDepartment of Urology, Istanbul Medipol University, Istanbul, Turkey.
Thomas J PolascikDivision of Urology, Duke University Medical Center, Durham, NC. Electronic address: thomas.polascik@duke.edu.
Focal Therapy Group Authors
Duke Medical Center · USInstitute Mutualiste Montsouris · FRJohns Hopkins University · USUniversity of Southern California · USIstanbul Medipol University · TRAC Diagnostics (United States) · USNational Cancer Institute · USNew York University · USNorthwell Health · USThe University of Texas MD Anderson Cancer Center · USUniversity College London · GBUniversity of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Cincinnati · USUniversity of Michigan–Ann Arbor · USUniversity of Toronto · CA

Funding

Prostate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2M
Translational Research in Surgical OncologyT32CA093245 · NCI · DUKE UNIVERSITY · PI ALLEN, PETER J, HARPOLE, DAVID H. · 2002 to 2020
$5.2M
NCI NIH HHS T32 CA093245
6 · The paper itself

Abstract

backgroundWith the advancement of imaging technology, focal therapy (FT) has been gaining acceptance for the treatment of select patients with localized prostate cancer (CaP). We aim to provide details of a formal physician consensus on the utilization of FT for patients with CaP who are discontinuing active surveillance (AS).

methodsA 3-stage Delphi consensus on CaP and FT was conducted. Consensus was defined as agreement by ≥80% of physicians. An in-person meeting was attended by 17 panelists to formulate the consensus statement.

resultsFifty-six respondents participated in this interdisciplinary consensus study (82% urologist, 16% radiologist, 2% radiation oncology). The participants confirmed that there is a role for FT in men discontinuing AS (48% strongly agree, 39% agree). The benefit of FT over radical therapy for men coming off AS is: less invasive (91%), has a greater likelihood to preserve erectile function (91%), has a greater likelihood to preserve urinary continence (91%), has fewer side effects (86%), and has early recovery post-treatment (80%). Patients will need to undergo mpMRI of the prostate and/or a saturation biopsy to determine if they are potential candidates for FT. Our limitations include respondent's biases and that the participants of this consensus may not represent the larger medical community.

conclusionsFT can be offered to men coming off AS between the age of 60 to 80 with grade group 2 localized cancer. This consensus from a multidisciplinary, multi-institutional, international expert panel provides a contemporary insight utilizing FT for CaP in select patients who are discontinuing AS.

Indexed as

Delphi TechniqueAblation TechniquesAgedAged, 80 and overConsensusHumansMaleMiddle AgedProstatic NeoplasmsWatchful WaitingActive surveillanceFocal therapyLocalized prostate cancerPartial gland ablation

Identifiers

PMID33676851
PMCPMC8654321
OpenAlexW3135481067

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.